JAMA Psychiatry ( IF 22.5 ) Pub Date : 2018-01-01 , DOI: 10.1001/jamapsychiatry.2017.3493 Julie M. Zito 1, 2 , Mehmet Burcu 1, 3 , Stephen McKean 4 , Rob Warnock 4 , Jeffrey Kelman 5
|
In response to the growing cardiometabolic safety concerns about the use of atypical antipsychotic (AAP) medications in children,1,2 several state Medicaid agencies have adopted a novel, more clinically nuanced and individualized approach to reviewing the appropriateness of AAP use, namely, peer review prior authorization (PA) policies.3 Physicians must receive preapproval through contracted clinicians (peer reviewers) to prescribe AAPs to certain-aged children. We assessed the effect of peer review PA policies on AAP use among Medicaid-insured youth according to age restriction criteria.
中文翻译：
医疗补助同行评审实施前后的小儿抗精神病药物的使用
在回答关于使用非典型抗精神病药物（AAP）的儿童药物，日益增长的心脏代谢安全问题1 ，2个几个州医疗机构已经采用了新的，更加临床细致入微和个性化的方法来审查AAP使用的适宜性，即，同行查看事先授权（PA）政策。3医生必须通过合同医生（同行评审员）的事先批准才能为某些年龄的儿童开具AAP。我们根据年龄限制标准评估了同行评审的PA政策对接受医疗补助的年轻人中AAP使用的影响。
京公网安备 11010802027423号